Presently, there are more than 10 approved gene therapies; over 465 product candidates are being eva

Encouraging clinical results across various metabolic, hematological and ophthalmic disorders have inspired research groups across the world to focus their efforts on the development of novel gene editing therapies. In fact, the gene therapy pipeline has evolved significantly over the past few years, with three products being approved in 2019 alone; namely Beperminogene perplasmid (AnGes), ZOLGENSMA® (AveXis) and ZYNTEGLO™ (bluebird bio). Further, there are multiple pipeline candidates in mid to late-stage (phase II and above) trials that are anticipated to enter the market over the next 5-10 years.

To order this 670+ page report, which features 190+ figures and 340+ tables, please visit this link 

The USD 11.6 billion (by 2030) financial opportunity within the gene therapy market has been analyzed across the following segments:

Key therapeutic areas

Autoimmune disorders

Cardiovascular diseases

Genetic disorders

Hematological disorders

Metabolic disorders

Ophthalmic disorders

Oncological disorders


  • Type of vector
  • Adeno associated virus
  • Adenovirus
  • Herpes simplex virus type 1
  • Lentivirus
  • Plasmid DNA
  • Retrovirus
  • Vaccinia Virus

Type of therapy

  • Ex vivo
  • In vivo

Type of gene modification

  • Gene augmentation
  • Immunotherapy
  • Oncolytic therapy
  • Others

Route of administration

  • Intraarticular
  • Intracerebellar
  • Intramuscular
  • Intradermal
  • Intravenous
  • Intravitreal
  • Intravesical
  • Subretinal
  • Others

Key geographical regions

North America



The Gene Therapy Market (3rd Edition), 2019-2030 report features the following companies, which we identified to be key players in this domain:

  • Advantagene
  • Advaxis
  • BioMarin
  • bluebird bio
  • FKD Therapies
  • Freeline Therapeutics
  • GenSight Biologics
  • Gradalis
  • Inovio Pharmaceuticals
  • Marsala Biotech
  • Orchard Therapeutics
  • Pfizer
  • Sarepta Therapeutics
  • Spark Therapeutics
  • Tocagen
  • Transgene
  • uniQure Biopharma
  • VBL Therapeutics
  • ViroMed

Table of Contents


1. Preface

2. Executive Summary


3. Introduction


4. Gene Delivery Vectors


5. Regulatory Landscape and Reimbursement Scenario


6. Competitive Landscape


7. Marketed Gene Therapies


8. Key Commercialization Strategies


9. Late Stage (Phase II/III and Above) Gene Therapies


10. Emerging Technologies


11. Promising Therapeutics Areas


12. Patent Analysis


13. Mergers and Acquisitions


14. Funding and Investment Analysis


15. Cost Price Analysis


16. Big Pharma Players: Analysis of Gene Therapy Related Initiatives


17. Market Forecast and Opportunity Analysis


18. Vector Manufacturing


19. Case Study: Gene Therapy Supply Chain


20. Conclusion


21. Interview Transcripts


22. Appendix 1: Tabulated Data


23. Appendix 2: List of Companies and Organizations

To purchase a copy, please visit

Contact Details

Gaurav Chaudhary

+1 (415) 800 3415

This post was created with our nice and easy submission form. Create your post!


Leave a Reply

Your email address will not be published. Required fields are marked *

GIPHY App Key not set. Please check settings



What do you think?

Grayscale owns 150% of bitcoin mined in January

Grayscale owns 150% of bitcoin mined in January

Ray Dalio: Bitcoin Could "Serve As a Diversifier to Gold"

Ray Dalio: Bitcoin Could “Serve As a Diversifier to Gold”